Nbr. 229, October 2007
> SIGN UP FREE
- The real stuff.
- Why Comp Criticism is Valid.
- Colonel who?
- Optimism at odds.
- Listen--and learn.
- Global guru.
- Fertilizer foes settle fight.
- Ditching diversification.
- Thorns & roses.
- Record drop in CEO confidence continues.
- The numbers.
- Fixing the biotech marketplace: generic biologic drugs could save billions.
- The making of a U.S. CEO: what can business executives learn from political candidates?
- Succession without tears: what does it take to manage a smooth leadership transition?
- That Vasella fella: Swiss drugmaker Novartis has brought 16 new drugs to market in the U.S. since 2000, compared to 13 for Pfizer and 9 for Merck. Now CEO Daniel Vasella is using biologics as a platform for the next stage of growth.
- Apology and forgiveness: how do you regain customer trust when things go wrong?
- Davos or denial: should a CEO bother with the World Economic Forum's annual meeting in Davos, Switzerland--where the hype is thick, the air is thin and the opportunities for relationship building tend to trump the content? Yes, but first prepare.
- Top 10 enterprise risks: what potential threats keep CEOs up at night?
- 2007 Chief Executive of the Year.
- The lure of the vines: why CEOs make the move from executive suite to wine celler.
- Executive action: the CEOs Without Borders concept gets a reality check.
- Nothing to fear from Free Trade.
- When transparency is anything but.